Avista supporting cGMP manufacture of hapten for opioid vaccine development

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/Remains)
(Image: iStock/Remains)

Related tags Vaccine Contract

Avista Pharma Solutions, Inc. has been contracted to manufacture an opioid-derived small molecule, which is a component of a conjugate vaccine being developed to treat opioid addiction.

The vaccine is being developed by the Minneapolis Medical Research Foundation (MMRF), a non-profit subsidiary of the Hennepin Healthcare System, Inc. in Minneapolis, MN.

The research is funded by a three-year grant to the MMRF from the National Institute on Drug Abuse and will “help with the unbiased epidemic that is causing great damage to the people of this country and around the world​,” Tim Compton, Avista’s vice president of business development told Outsourcing-Pharma.com.

Under the services agreement, Avista Pharma Solutions​ will support the development and manufacturing of the small molecule (hapten​) associated with the vaccine.

The contract development and manufacturing organization (CDMO) will produce a cGMP batch of the molecule to support manufacturing of the vaccine and finished dosage form for the first-in-human studies.

Currently we are engaged through the first phase in human production of the hapten, but hope to continue supporting and working with MMRF as future development milestones are achieved​,” explained Compton.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Webinars

Headlines